In the BioHarmony Drug Report Database

"Preview" Icon

Tivozanib

Fotivda (tivozanib) is a small molecule pharmaceutical. Tivozanib was first approved as Fotivda on 2017-08-24. It is used to treat renal cell carcinoma in the USA. It has been approved in Europe to treat renal cell carcinoma. The pharmaceutical is active against vascular endothelial growth factor receptor 2, vascular endothelial growth factor receptor 3, and vascular endothelial growth factor receptor 1. Fotivda’s patents are valid until 2023-11-16 (FDA).

 

Trade Name

 

Fotivda
 

Common Name

 

tivozanib
 

ChEMBL ID

 

CHEMBL1289494
 

Indication

 

renal cell carcinoma
 

Drug Class

 

Angiogenesis inhibitors

Image (chem structure or protein)

Tivozanib structure rendering